BioCina Names Dr. Thomas Broudy as CEO

BioCina, a pharmaceutical contract development and manufacturing organization (CDMO), has appointed Dr. Thomas Broudy as Chief Executive Officer to lead the company’s growth of its biologic drug substance and sterile drug product development and manufacturing services.

Broudy brings over 20 years of experience in the biopharmaceutical and CDMO industries, spanning operations, business development, and strategic leadership.

“BioCina is entering an exciting new chapter,” said Dr. Masood Tayebi, Co-Founder and CEO of Bridgewest Group. “Tommy’s deep understanding of our business, his global industry experience, and his proven track record of leadership make him the right person to guide BioCina’s continued growth and innovation. The Board has full confidence in his ability to build on the strong foundation we have established and lead the company into its next phase.”

Experience

Broudy’s background spans the full drug development value chain, including executive roles at both innovative biotech and outsourced service providers. He has been with Bridgewest Group and Bridgewest Group portfolio companies over the past 15 years.

Most recently as BioCina’s Chairman of the Board, he was involved in shaping BioCina’s vision and provided operational leadership to the drug substance and drug product businesses.

He was Executive Vice President, Corporate Development & Marketing at BioDuro-Sundia, a Bridgewest Group portfolio company, leading the go-to-market strategy for the 2,500-person integrated CRDMO.

Under the Bridgewest Group umbrella, he previously co-founded and served as CSO of Molecular Response, a specialized contract research organization, which culminated in a strategic acquisition by Crown Bioscience where he continued as General Manager contributing to a successful IPO on Taipei Exchange.

He previously served as CEO of January Therapeutics, a biotech focused on novel nanoparticle formulations. Earlier in his career, he held commercial roles at AltheaDx and Affymetrix, leading genomics and diagnostics companies.

Broudy has a technical background as well, having held postdoctoral appointments at Rockefeller University and Stanford University studying host/microbial genomics. He earned his PhD at Rockefeller in the Laboratory of Bacterial Pathogenesis and Immunology.

“I am honored to lead BioCina and continue advancing our mission to deliver world-class CDMO services,” said Broudy. “BioCina’s talented team, scientific excellence, and client-centric focus position us to grow as a trusted global CDMO partner. I look forward to working closely with our employees, clients, and stakeholders as we pursue this next phase of growth.”